SUBSCRIBE
SUBSCRIBE

Kansas

PRESS RELEASES
Press Releases
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
November 8, 2024
 · 
7 min read
Press Releases
Cingulate Announces Adjournment of Special Meeting
October 10, 2024
 · 
2 min read
Press Releases
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301
September 12, 2024
 · 
6 min read
Business
Cingulate to Participate in Benzinga All Live Access Event
August 27, 2024
 · 
1 min read
Press Releases
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
August 15, 2024
 · 
5 min read
Press Releases
Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved
August 13, 2024
 · 
9 min read
Business
Mosaic Diagnostics Appoints Healthcare Industry Veteran Rob Rebak as CEO
June 27, 2024
 · 
3 min read
Drug Development
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
May 21, 2024
 · 
8 min read
Business
Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
May 8, 2024
 · 
6 min read
Business
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
April 30, 2024
 · 
3 min read
Business
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
April 1, 2024
 · 
9 min read
Drug Development
Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression
March 13, 2024
 · 
3 min read
BioMidwest
Cingulate to Attend DCAT Week 2024 in New York City
March 6, 2024
 · 
7 min read
Business
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 13, 2024
 · 
8 min read
BioMidwest
Cingulate Announces Closing of $7.5 Million Public Offering
February 6, 2024
 · 
4 min read
BioMidwest
Cingulate Announces Pricing of $7.5 Million Public Offering
February 2, 2024
 · 
4 min read
Business
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
January 29, 2024
 · 
3 min read
BioMidwest
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024
 · 
7 min read
Business
Kansas City Proton Institute Begins Cancer Treatments with Advanced MEVION S250i Proton Therapy System
December 22, 2023
 · 
5 min read
Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)
December 1, 2023
 · 
6 min read
Load More